LQDA NASDAQ
Liquidia Corporation
1W: -58.1%
1M: -58.9%
3M: -63.8%
YTD: -8.8%
1Y: +29.9%
3Y: +348.2%
5Y: +897.9%
$28.64
+0.65 (+2.32%)
Weekly Expected Move ±29.6%
$12
$20
$29
$37
$46
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.21
Neutral
4 bullish
2 neutral
7 bearish
Articles (7d)
13
Daily Sentiment (7 Days)
Articles (100)
Liquidia extends losses as Wells Fargo adds to downgrades on legal setback
Liquidia (NASDAQ:LQDA) Shares Gap Down Following Analyst Downgrade
Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback
Liquidia cut to Neutral at BTIG after patent win for United Therapeutics
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%
Biggest stock movers Thursday: ACN, INGN, and more
These ten healthcare stocks posted the biggest one-month losses
Liquidia plunges 57% on litigation update
LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now?
Liquidia plunges amid court ruling in United Therapeutics patent fight
Liquidia (NASDAQ:LQDA) Shares Up 4.2% – Time to Buy?
9,513 Shares in Liquidia Corporation $LQDA Bought by Corient Private Wealth LP
Liquidia rises 8% amid broader strength in biotech peers
Can LQDA's Yutrepia Outpace Intensifying PAH Competition?
California State Teachers Retirement System Acquires 5,835,156 Shares of Liquidia Corporation $LQDA
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?
Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio?
Liquidia Corporation’s (LQDA) Yutrepia Launch Continues to Outpace the Expectations
FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis
Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?
Is the Options Market Predicting a Spike in Liquidia Stock?
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?
Will LQDA's Differentiated PAH Approach Drive Growth?
Can Yutrepia's Strong Growth Drive Liquidia's PAH Expansion?
Liquidia (LQDA) Q2 2026 Earnings Call Transcript
Handelsbanken Fonder AB Invests $1.99 Million in Liquidia Corporation $LQDA
LQDA Stock Down Post Q2 Earnings Release: What Should Investors Do Now?
FY2026 EPS Estimates for Liquidia Reduced by HC Wainwright
Why Liquidia Stock Was Diving This Week
LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus
LQDA Q2 Earnings Call Highlights YUTREPIA and $1B 2027 Revenue Path
Liquidia Corporation Q2 2026 Earnings Call Summary
ALKS Stock Rises 27% in 3 Months: Here's What You Should Know
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA
Liquidia Corporation (LQDA) Q2 Earnings and Revenues Beat Estimates
Liquidia Corporation Reports Second Quarter 2026 Financial Results
Here are the major earnings before the open Wednesday
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates
Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus
Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues
BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge
KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema
ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut
OTLK Up More Than 300% in 3 Months: Here's What You Should Know
Here's Why Replimune Stock Skyrockets Nearly 223% in 3 Months
3 Low-Beta Stocks to Minimize Portfolio Risk: LQDA, PBF & FET
Quant snapshot: Lenovo Group and Lumentum Holdings lead top-rated names as Cannae Holdings and Crescent Capital BDC Payments lag
SA Asks: What's the outlook for Big Pharma M&A?
Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up
Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls
Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised
BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised
NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues
Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri Uptake
XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus
IOVA Q2 Earnings Beat, Stock Jumps 43% on Strong Amtagvi Uptake
Perrigo Stock Rises 23% as Q2 Earnings & Sales Beat Estimates
Zoetis Q2 Earnings Beat Estimates, Revenues Miss, 2026 View Cut
VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales Jump
EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus
Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress
Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
ADMA Q2 Earnings Meet, Revenues Miss on Bivigam Weakness
United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark
Zacks Investment Ideas feature highlights: Lenovo, Victoria's Secret and Liquidia
HRMY Q2 Earnings Beat Estimates on Strong Wakix Sales, Stock Up
3 Top Ranked Stocks Breaking Out Now
Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut
Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Y
ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales
BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus
SYRE's Q2 Loss Narrower Than Expected, Pipeline Progresses
NVO Stock Down Despite Q2 Earnings and Sales Beat on GLP-1 Growth
IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook
Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus
CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus
TGTX Q2 Earnings Lag, Sales Rise Y/Y, 2026 View Raised, Stock Down
Should You Invest in Liquidia Corporation Stock Ahead of Q2 Earnings?
AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year
MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth
AMRX Down Despite Q2 Earnings Beat, 2026 Revenue Outlook Raised
BMY Q2 Earnings Beat Estimates, '26 View Raised, Stock Up
VKTX Q2 Earnings Beat Estimates Despite Surge in R&D Costs
BHC Q2 Earnings Beat Estimates on Salix and Solta Growth, '26 View Raised
Teva Q2 Earnings Lag Estimates, 2026 Revenue View Raised, Stock Rises
CORT Q2 Earnings & Revenues Beat Estimates, 2026 Outlook Raised
QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
Repligen Beats Q2 Earnings Estimates, Raises 2026 View, Stock Up
Amarin's Q2 Earnings Beat Estimates, Revenues Fall Short
GSK Beats Q2 Earnings & Revenue Estimates, Announces Cost-Saving Plan
Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down
Liquidia Corporation (LQDA) Has 50%+ Upside on Yutrepia Ruling and Buyout Potential
Zacks.com featured highlights include Liquidia, Energy Transfer and PBF Energy
FY2027 EPS Estimates for Liquidia Boosted by HC Wainwright